DULOXETINE BOEHRINGER INGELHEIM og placebo.
In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with DULOXETINE BOEHRINGER INGELHEIM and 24% of patients taking placebo.